Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Sanofi Ord Shs SNYNF

Healthcare

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood... see more

Add To Watchlist

Recent & Breaking News (OTCPK:SNYNF)

Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

PR Newswire July 30, 2014

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

PR Newswire July 30, 2014

Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States

PR Newswire July 22, 2014

Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis

PR Newswire July 9, 2014

FDA Accepts Sanofi's New Drug Application for Basal Insulin Toujeo®

PR Newswire July 8, 2014

JuniorSTAR(TM) insulin pen designed to help young people living with diabetes take greater control of their lives

Canada NewsWire July 2, 2014

CureVac Signs an Exclusive License Agreement with Sanofi Pasteur to Develop and Commercialize an mRNA-based Prophylactic Vaccine

PR Newswire July 1, 2014

Kids at risk of severe allergies attend soccer clinic hosted by the Montreal Impact and Allerject(TM)

Canada NewsWire June 30, 2014

Genzyme's Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis

Business Wire June 30, 2014

IPO Report: Amphastar Pharmaceuticals (AMPH)

Equities.com June 24, 2014

CrowdGather: Diversified Play on High-Growth Social Gaming

Accesswire June 17, 2014

TEENs Study Shows Achieving Target Blood Sugar Levels is Associated with Better Quality of Life for Young People with Type 1 Diabetes

Canada NewsWire June 16, 2014

Sanofi's Lyxumia(R) (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering Than Liraglutide When Both Were Added to Insulin Glargine

PR Newswire June 16, 2014

Allerject(TM) - now we're talking! Canadians at risk of anaphylaxis and those who care for them are choosing Allerject(TM) as their emergency treatment option

Canada NewsWire June 16, 2014

Sanofi Announces Positive Phase 3 Results for Toujeo(R) (insulin glargine [rDNA origin] injection, 300 U/mL) in Japanese People with Uncontrolled Diabetes

PR Newswire June 16, 2014

Sanofi's Lyxumia® (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering Than Liraglutide When Both Were Added to Insulin Glargine

Canada NewsWire June 14, 2014

Sanofi Announces Positive Phase 3 Results for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) in Japanese People with Uncontrolled Diabetes

Canada NewsWire June 14, 2014

Sanofi Reports Positive Phase 3 Results for Toujeo(R)

GlobeNewswire June 14, 2014

Patients Continuing On Sanofi's Lantus® Had Lower Blood Sugar Levels Than Those who Switched to Insulin Detemir

PR Newswire June 14, 2014

Sanofi Reports Positive Phase 3 Results for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL)

PR Newswire June 14, 2014